Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 11067 - cryosurgical unit, general-purpose - a unit that applies a gaseous or liquid refrigerant to withdraw heat from target tissues or indirectly through contact with cryogen-cooled probe.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hoyland medical pty ltd - 11067 - cryosurgical unit, general-purpose - cryosurgery machine is designed to freeze cells and muscosal tissue with the use of co2 or no2 gas. with an applicator with specially designed tips. commonly used in gynaecology, ophthalmics and dermatology.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 11067 - cryosurgical unit, general-purpose - a cryotherapy device intended to be used for the ablation of tissue in the nasal cavity in patients with chronic rhinitis symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 11067 - cryosurgical unit, general-purpose - this device is used for the removal of warts and other benign skin lesions: genital lesions, molluscum contagiosum, seborrheic keratoses, skin tags, verruca plantaris, verruca vulgaris, verruca plana, actinic keratoses (facial and non-facial), and lentigo (facial and non-facial).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pentax medical singapore pte ltd - 11067 - cryosurgical unit, general-purpose - to ablate unwanted tissue in the gastrointestinal tract, including treatment of barrett?s oesophagus and squamous dysplasia, by application of extreme cold

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 11067 - cryosurgical unit, general-purpose - this device is intended for the surgical destruction of target tissue by applying cryogenic gases at extreme low temperatures. the list below shows examples of the typical lesions that can be treated verruca seborrheic keratoses achrochordon age spots small keloids porokeratosis angiomas keratoacanthoma lentigo discrete epithelial nevus granuloma pyogenicum plantar warts actinic keratoses molluscum contagiosum dermafibroma granuloma annulare lentigo maligna bowen?s disease chondrodermatitis leukoplakia pyogenic granuloma

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

kinetik pty ltd - ct945 - general laboratoryware ivds - in vitro diagnostic (ivd) laboratory reagents; class i collective term ?l1 ct - ct945 general laboratoryware ivd?: (including those named) under l2ct ct215 biological stain ivd being provided as class i ivd; providing that a) the products are sold individually and not as kits or kit components and b) the instructions for performing the staining procedure are not supplied. includes biomedical stains and solutions, specifically those that may be used in laboratories undertaking examination of clinical and/or other samples in realtion to haematology, microbiology, cytology, histology and/or immunology.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 50.1 mg (equivalent: sunitinib, qty 37.5 mg) - capsule - excipient ingredients: propylene glycol; iron oxide black; isopropyl alcohol; butan-1-ol; ammonia; ethanol absolute; titanium dioxide; povidone; purified water; potassium hydroxide; mannitol; shellac; croscarmellose sodium; iron oxide yellow; magnesium stearate; sodium lauryl sulfate; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 66.8 mg (equivalent: sunitinib, qty 50 mg) - capsule - excipient ingredients: sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; shellac; povidone; magnesium stearate; sodium hydroxide; gelatin; iron oxide black; iron oxide red; propylene glycol; mannitol; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: sodium hydroxide; titanium dioxide; mannitol; shellac; sodium lauryl sulfate; iron oxide red; propylene glycol; povidone; croscarmellose sodium; magnesium stearate; gelatin; iron oxide black; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).